<DOC>
	<DOC>NCT01814267</DOC>
	<brief_summary>The aim of the study is to assess the cost-effectiveness of telemedicine in the care of chronic diabetic foot ulcers. Patients will be randomized into 2 groups: 1/conventional care group with iterative visits to diabetes specialist or 2/innovative care (telemedicine group). the health insurance system perspective is adopted.</brief_summary>
	<brief_title>Medico-economical Assessment of Telemedicine During Chronic Diabetes-related Foot Wound Management</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Patients with type 1 or 2 diabetes, at least 18 years old Patient with a diabetic foot wound : Acute or chronic (evolving for at least 30 days) size ≤ to 3 cm² Level I, II or III, stage A or B, excluding stages C and D from the University of Texas Wound Classification Systems Person affiliated to French Health insurance or equivalent Person having signed freely the consent form after receiving sufficient information Treatment compliance and 6 months followup feasible Patient with a ischemic wound: AnkleBrachial Index (ABI) &lt;0.9 or Transcutaneous oxygen pressure (TcpO2) &lt; 30 mmHg (stage C and D from the University of Texas Wound Classification Systems) Patient with emergency hospitalization indication whatever the reasons. Person deprived of liberty by a legal or administrative decision, patients in emergency and people hospitalised without consent and who are not protected by law. Pregnant or breastfeeding women Patient currently participating in another telemedicine research protocol (such as : Study on the impact of Telemedicine on the management of patients with type 1 diabetes (TELEDIAB3))</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>innovative care</keyword>
	<keyword>telemedicine</keyword>
	<keyword>cost effectiveness</keyword>
	<keyword>diabetes</keyword>
</DOC>